Compile Data Set for Download or QSAR
maximum 50k data
Found 425 with Last Name = 'scorah' and Initial = 'n'
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50:  0nMAssay Description:Inhibition of human Jak3More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50:  0nMAssay Description:Inhibition of human EGFRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50:  0nMAssay Description:Inhibition of human ITKMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238063(CHEMBL4101751)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238082(CHEMBL4102696)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350340((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350343((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350343((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350340((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350338((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-fluoro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350339((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-fluo...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350339((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-fluo...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350338((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-fluoro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: >2nMAssay Description:Inhibition of Btk (unknown origin) assessed as inhibition of phosphorylation of FAM-labelled peptide substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: <2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: <2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238072(CHEMBL4104104)
Affinity DataIC50:  2nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238093(CHEMBL4094958)
Affinity DataIC50:  2.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238056(CHEMBL4060987)
Affinity DataIC50:  2.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350345((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-meth...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350346((S)-3-(6-((1-acryloylpyrrolidin-3-yl)oxy)-4-methyl...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350350((S)-5-(1-((1-(2-chloroacetyl)pyrrolidin-3-yl)amino...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350324((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)isoquin...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350333((S)-3-(8-((1-acryloylpyrrolidin-3-yl)amino)-1,7-na...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350336(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350341((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-fluo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350342((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350344((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350345((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-meth...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350346((S)-3-(6-((1-acryloylpyrrolidin-3-yl)oxy)-4-methyl...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350344((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350342((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350341((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-fluo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350336(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350333((S)-3-(8-((1-acryloylpyrrolidin-3-yl)amino)-1,7-na...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350350((S)-5-(1-((1-(2-chloroacetyl)pyrrolidin-3-yl)amino...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350324((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)isoquin...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity mitogen-activated protein kinase kinase 1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50337934((R)-3-(2,3-dihydroxypropoxy)-6-fluoro-5-(2-fluoro-...)
Affinity DataIC50:  3.10nMAssay Description:Inhibition of MEK1 by IMAP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350332((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...)
Affinity DataIC50: <3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350332((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...)
Affinity DataIC50: <3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350327((S)-3-(1-((1-acryloylpyrrolidin-3-yl)(methyl)amino...)
Affinity DataIC50:  3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350327((S)-3-(1-((1-acryloylpyrrolidin-3-yl)(methyl)amino...)
Affinity DataIC50:  3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238064(CHEMBL4063730)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238074(CHEMBL4075003)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDual specificity mitogen-activated protein kinase kinase 1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50337926((R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4...)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of MEK1 by IMAP assayMore data for this Ligand-Target Pair
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50238084(CHEMBL4085333)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of recombinant N-terminal GST tagged human ALK5 (200 to 503 residues) expressed in baculovirus expression system using FAM-NH2-KVLTQMGSPSI...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDual specificity mitogen-activated protein kinase kinase 1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50337929((S)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4...)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of MEK1 by IMAP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50533233(CHEMBL4447510)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of ALK5 (unknown origin) using fluorescein-labeled peptide substrate incubated for 90 mins by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50533233(CHEMBL4447510)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of ALK5 (unknown origin) using fluorescein-labeled peptide substrate incubated for 90 mins by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetDual specificity mitogen-activated protein kinase kinase 1(Homo sapiens (Human))
Takeda California

Curated by ChEMBL
LigandPNGBDBM50337933(3-(1,3-dihydroxypropan-2-yl)-6-fluoro-5-(2-fluoro-...)
Affinity DataIC50:  3.30nMAssay Description:Inhibition of MEK1 by IMAP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 425 total ) | Next | Last >>
Jump to: